Compare IPCA Labs with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs AJANTA PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS AJANTA PHARMA IPCA LABS/
AJANTA PHARMA
 
P/E (TTM) x 22.9 22.5 101.5% View Chart
P/BV x 4.4 3.9 112.8% View Chart
Dividend Yield % 0.3 0.9 30.5%  

Financials

 IPCA LABS   AJANTA PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
AJANTA PHARMA
Mar-19
IPCA LABS/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0421,422 73.3%   
Low Rs590898 65.7%   
Sales per share (Unadj.) Rs298.6233.5 127.9%  
Earnings per share (Unadj.) Rs35.044.0 79.6%  
Cash flow per share (Unadj.) Rs49.452.2 94.8%  
Dividends per share (Unadj.) Rs3.009.00 33.3%  
Dividend yield (eoy) %0.40.8 47.4%  
Book value per share (Unadj.) Rs247.1255.1 96.9%  
Shares outstanding (eoy) m126.3588.02 143.5%   
Bonus/Rights/Conversions ESOSBB-  
Price / Sales ratio x2.75.0 55.0%   
Avg P/E ratio x23.326.4 88.4%  
P/CF ratio (eoy) x16.522.2 74.2%  
Price / Book Value ratio x3.34.5 72.6%  
Dividend payout %8.620.5 41.9%   
Avg Mkt Cap Rs m103,108102,081 101.0%   
No. of employees `00013.46.8 197.7%   
Total wages/salary Rs m7,8744,307 182.8%   
Avg. sales/employee Rs Th2,807.03,022.6 92.9%   
Avg. wages/employee Rs Th585.8633.4 92.5%   
Avg. net profit/employee Rs Th329.0569.1 57.8%   
INCOME DATA
Net Sales Rs m37,73220,554 183.6%  
Other income Rs m577211 273.6%   
Total revenues Rs m38,30920,765 184.5%   
Gross profit Rs m6,9015,664 121.8%  
Depreciation Rs m1,824721 253.1%   
Interest Rs m18912 1,626.7%   
Profit before tax Rs m5,4655,143 106.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0421,273 81.9%   
Profit after tax Rs m4,4223,870 114.3%  
Gross profit margin %18.327.6 66.4%  
Effective tax rate %19.124.8 77.1%   
Net profit margin %11.718.8 62.3%  
BALANCE SHEET DATA
Current assets Rs m23,77811,812 201.3%   
Current liabilities Rs m10,9753,776 290.6%   
Net working cap to sales %33.939.1 86.8%  
Current ratio x2.23.1 69.3%  
Inventory Days Days10477 134.1%  
Debtors Days Days6682 80.8%  
Net fixed assets Rs m20,36814,398 141.5%   
Share capital Rs m253175 144.1%   
"Free" reserves Rs m30,97122,277 139.0%   
Net worth Rs m31,22422,452 139.1%   
Long term debt Rs m1,4097 21,340.9%   
Total assets Rs m45,50726,962 168.8%  
Interest coverage x30.0444.3 6.7%   
Debt to equity ratio x00 15,345.6%  
Sales to assets ratio x0.80.8 108.8%   
Return on assets %10.114.4 70.4%  
Return on equity %14.217.2 82.2%  
Return on capital %17.323.0 75.5%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30810,682 162.0%   
Fx outflow Rs m6,2662,102 298.1%   
Net fx Rs m11,0428,580 128.7%   
CASH FLOW
From Operations Rs m4,9233,748 131.4%  
From Investments Rs m-1,563-2,228 70.2%  
From Financial Activity Rs m-1,832-1,475 124.2%  
Net Cashflow Rs m1,52845 3,379.9%  

Share Holding

Indian Promoters % 45.9 73.8 62.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 1.6 735.5%  
FIIs % 25.3 7.6 332.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 17.0 102.4%  
Shareholders   36,892 20,968 175.9%  
Pledged promoter(s) holding % 2.1 4.4 48.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  WYETH LTD  TORRENT PHARMA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Flat; L&T and Tech Mahindra Top Losers(12:30 pm)

Share markets in India are presently trading on a volatile note. Sectoral indices are trading mixed with stocks in the capital goods sector and realty sector.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Nov 13, 2019 01:17 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS